



29 January 2018

ASX Announcement / Media Release

Notice of Allowance for Bisantrene Patent in US

HIGHLIGHTS

- US Patent Office grants Notice of Allowance on key Bisantrene patent
- Greatly extends commercial exclusivity period for Bisantrene in US

29 January 2018: Race Oncology Limited (“RAC”) is pleased to announce that a key Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent.

The patent titled, “Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof,” is one of two Bisantrene patents filed in the US, Europe and five other key countries. The US is the first jurisdiction to allow the patent. The second Bisantrene patent is still under examination with the US Patent Office.

“We are very pleased to see our first patent allowed in the world’s most important pharmaceutical market – the US,” said Race CEO, Peter Molloy.

This patent provides commercial protection for Bisantrene in the US through 2034.

“We already have Orphan Drug Designation in the US, which provides seven years of commercial exclusivity for Bisantrene from US FDA approval,” noted Mr Molloy. “This patent potentially doubles that exclusivity period in the US.”

The patent protects the use of Bisantrene in patients with refractory or relapsed cancers, including AML and related leukaemia (MDS, ALL, CLL), as well as breast cancer, lymphoma and other cancers. In summary, it provides commercial protection for all uses of Bisantrene currently contemplated by Race Oncology.



About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers. It has been shown to have greatly reduced cardiac toxicity and significantly diminished potential for resistance. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. The FDA has acknowledged that Race's Bisantrene program meets the criteria as a 505(b)(2) program. Race has filed two patents on the drug and has been granted an Orphan Drug Designation in the USA for AML, which confers seven years of market exclusivity in the US from the date of FDA approval.

About Bisantrene Patents

Race Oncology owns two patents on Bisantrene: (1) "Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof," and (2) "Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof." The two patents filed between 2014 and 2016 in United States (US), Europe, Canada, China, South Korea, Australia and New Zealand. If granted, both patents will last 20 years from filing, expiring in 2034. Both patents are wholly-owned by Race Oncology with no royalty obligations to any third party.

About Race Oncology (RAC: ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The Company's first asset is Bisantrene, a chemotherapy drug, that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of pharmaceutical mergers.

Media contact:

Heidi Cuthbert

+61 411 272 366

E: heidi.cuthbert@multiplier.com.au